Atricure Stock Analysis
ATRC Stock | USD 29.26 0.49 1.65% |
AtriCure is undervalued with Real Value of 34.76 and Target Price of 49.89. The main objective of AtriCure stock analysis is to determine its intrinsic value, which is an estimate of what AtriCure is worth, separate from its market price. There are two main types of AtriCure's stock analysis: fundamental analysis and technical analysis.
The AtriCure stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and AtriCure's ongoing operational relationships across important fundamental and technical indicators.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. AtriCure Stock Analysis Notes
About 97.0% of the company shares are held by institutions such as insurance companies. The book value of AtriCure was presently reported as 9.19. The company recorded a loss per share of 0.81. AtriCure last dividend was issued on the 30th of September 2010. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Atricure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 875 people. For more info on AtriCure please contact Michael Carrel at 513 755 4100 or go to https://www.atricure.com.AtriCure Quarterly Total Revenue |
|
AtriCure Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. AtriCure's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding AtriCure or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
AtriCure generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 465.31 M. Net Loss for the year was (44.7 M) with profit before overhead, payroll, taxes, and interest of 358.88 M. | |
Over 97.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from zacks.com: Abbott Q2 Earnings and Revenues Top Estimates |
AtriCure Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AtriCure previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024 Upcoming Quarterly Report | View | |
7th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
20th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
AtriCure Largest EPS Surprises
Earnings surprises can significantly impact AtriCure's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2013-08-01 | 2013-06-30 | -0.1 | -0.09 | 0.01 | 10 | ||
2012-08-02 | 2012-06-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2011-11-01 | 2011-09-30 | -0.08 | -0.07 | 0.01 | 12 |
AtriCure Environmental, Social, and Governance (ESG) Scores
AtriCure's ESG score is a quantitative measure that evaluates AtriCure's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of AtriCure's operations that may have significant financial implications and affect AtriCure's stock price as well as guide investors towards more socially responsible investments.
AtriCure Stock Institutional Investors
Shares | Nuveen Asset Management, Llc | 2024-12-31 | 1 M | Marshall Wace Asset Management Ltd | 2025-03-31 | 994.1 K | Fmr Inc | 2025-03-31 | 993 K | Gw&k Investment Management, Llc | 2025-03-31 | 981.5 K | Nuveen, Llc | 2025-03-31 | 950.6 K | Goldman Sachs Group Inc | 2025-03-31 | 862.7 K | Bnp Paribas Investment Partners Sa | 2025-03-31 | 747.8 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 711 K | Wellington Management Company Llp | 2025-03-31 | 702.1 K | Vanguard Group Inc | 2025-03-31 | 4.7 M | Blackrock Inc | 2025-03-31 | 4.2 M |
AtriCure Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.45 B.AtriCure Profitablity
The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.05) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.05.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.14) | (0.15) | |
Return On Capital Employed | (0.07) | (0.08) | |
Return On Assets | (0.07) | (0.08) | |
Return On Equity | (0.10) | (0.10) |
Management Efficiency
AtriCure has return on total asset (ROA) of (0.037) % which means that it has lost $0.037 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0838) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of July 19, 2025, Return On Tangible Assets is expected to decline to -0.15. In addition to that, Return On Capital Employed is expected to decline to -0.08. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 358.6 M, whereas Other Assets are forecasted to decline to 0.86.Last Reported | Projected for Next Year | ||
Book Value Per Share | 9.82 | 10.31 | |
Tangible Book Value Per Share | 3.61 | 3.79 | |
Enterprise Value Over EBITDA | (74.95) | (78.69) | |
Price Book Value Ratio | 3.11 | 3.71 | |
Enterprise Value Multiple | (74.95) | (78.69) | |
Price Fair Value | 3.11 | 3.71 | |
Enterprise Value | 73.6 M | 54.9 M |
The strategic initiatives led by AtriCure's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 19th of July, AtriCure shows the Risk Adjusted Performance of (0.04), standard deviation of 2.59, and Mean Deviation of 1.84. AtriCure technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.AtriCure Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of AtriCure for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out AtriCure short-term fluctuations and highlight longer-term trends or cycles.
AtriCure Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AtriCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AtriCure Outstanding Bonds
AtriCure issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AtriCure uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AtriCure bonds can be classified according to their maturity, which is the date when AtriCure has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
AtriCure Predictive Daily Indicators
AtriCure intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AtriCure stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 9287.54 | |||
Daily Balance Of Power | (0.52) | |||
Rate Of Daily Change | 0.98 | |||
Day Median Price | 29.69 | |||
Day Typical Price | 29.54 | |||
Price Action Indicator | (0.67) | |||
Period Momentum Indicator | (0.49) | |||
Relative Strength Index | 44.84 |
AtriCure Corporate Filings
F4 | 2nd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 30th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
29th of May 2025 Other Reports | ViewVerify | |
F4 | 21st of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of May 2025 Other Reports | ViewVerify | |
F4 | 7th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
5th of May 2025 Other Reports | ViewVerify |
AtriCure Forecast Models
AtriCure's time-series forecasting models are one of many AtriCure's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AtriCure's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About AtriCure Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how AtriCure prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AtriCure shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AtriCure. By using and applying AtriCure Stock analysis, traders can create a robust methodology for identifying AtriCure entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.09) | (0.10) | |
Operating Profit Margin | (0.09) | (0.09) | |
Net Loss | (0.10) | (0.10) | |
Gross Profit Margin | 0.75 | 0.58 |
Current AtriCure Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AtriCure analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AtriCure analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
49.89 | Strong Buy | 9 | Odds |
Most AtriCure analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AtriCure stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AtriCure, talking to its executives and customers, or listening to AtriCure conference calls.
AtriCure Stock Analysis Indicators
AtriCure stock analysis indicators help investors evaluate how AtriCure stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AtriCure shares will generate the highest return on investment. By understating and applying AtriCure stock analysis, traders can identify AtriCure position entry and exit signals to maximize returns.
Begin Period Cash Flow | 84.3 M | |
Long Term Debt | 61.9 M | |
Common Stock Shares Outstanding | 47 M | |
Total Stockholder Equity | 461 M | |
Total Cashflows From Investing Activities | 30.2 M | |
Tax Provision | 1 M | |
Property Plant And Equipment Net | 47.4 M | |
Cash And Short Term Investments | 122.7 M | |
Cash | 122.7 M | |
Accounts Payable | 25 M | |
Net Debt | -46.2 M | |
50 Day M A | 32.359 | |
Total Current Liabilities | 73.4 M | |
Other Operating Expenses | 505.3 M | |
Non Current Assets Total | 341.5 M | |
Non Currrent Assets Other | 2.9 M | |
Stock Based Compensation | 40.4 M |
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |